Cover Image
市場調查報告書

前列腺肥大症治療設備的全球市場:2015∼2019年

Global Benign Prostatic Hyperplasia Devices Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 331946
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
前列腺肥大症治療設備的全球市場:2015∼2019年 Global Benign Prostatic Hyperplasia Devices Market 2015-2019
出版日期: 2015年06月03日 內容資訊: 英文 71 Pages
簡介

所謂前列腺肥大特徵是非癌性前列腺細胞增殖,前列腺肥大造成尿道受壓迫及儲尿量受限的原因。高齡化及荷爾蒙平衡、異常的細胞增生下致病的因素,治療前列腺因要治療受堵塞尿道而需進行侵襲性手術。預測全球前列腺肥大症治療設備市場在2014年到2019年間將以年複合成長率(CAGR)5.05%的速度擴大。

本報告提供全球前列腺肥大症治療設備市場相關調查,提供您市場規模與趨勢,2015∼2019年的成長預測,各市場區隔趨勢,及加入此市場的主要企業簡介等資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

  • 市場概要
  • 產品概要

第4章 市場調查方法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 前列腺肥大症:概要

  • 發病率和罹患率
  • 主要的症狀

第8章 治療別市場區隔

  • TURP
  • 雷射手術
  • TUMT
  • TUNA
  • 前列腺支架
  • 其他

第9章 各地區市場市場區隔

  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第10章 購買標準

第11章 市場成長的促進要素

第12章 促進要素與其影響

第13章 市場課題

第14章 促進要素的影響與課題

第15章 市場趨勢

第16章 趨勢及其影響

第17章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2014年
  • 其他的潛力供應商

第18章 主要供應商分析

  • Endo International
  • Karl Storz
  • Lumenis
  • Olympus
  • Urologix

第19章 本系列的其他報告

圖表

目錄
Product Code: IRTNTR6113

About Benign Prostatic Hyperplasia Device

Benign prostatic hyperplasia is a condition characterized by non-cancerous proliferation of prostate gland cells. This causes the gland to enlarge and, as a result, press against the urethra, constricting urine flow. It is associated with aging, hormone imbalances, and abnormal cell growth. Benign prostatic hyperplasia device is used to perform invasive and MI surgeries to remedy a blocked urethra.

Technavio's analysts forecast the global benign prostatic hyperplasia devices market to grow at a CAGR of 5.05% percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and growth prospects of the global benign prostatic hyperplasia devices market for the period 2014-2019. The global benign prostatic hyperplasia devices market is divided into six segments based on procedure type: TURP, TUMT, TUNA, laser surgery, prostatic stenting, and others (water-induced thermotherapy, high-intensity frequency ultrasound, and open prostatectomy).

Technavio's report, Global Benign Prostatic Hyperplasia Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the global benign prostatic hyperplasia devices market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Endo Health Solutions
  • Karl Storz
  • Lumenis
  • Olympus
  • Urologix

Other Prominent Vendors

  • Boston Scientific
  • Coloplast
  • Lisa Laser
  • Medi-tate
  • Medifocus
  • Neotract
  • ProArc Medical
  • UroTech

Market Driver

  • Growing Elderly Population
  • For a full, detailed list, view our report

Market Challenge

  • Alternative Treatment Methods
  • For a full, detailed list, view our report

Market Trend

  • High Number of Outpatient Procedures
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Market Research Methodology

  • 04.1. Market research process
  • 04.2. Research methodology

05. Introduction

06. Market Landscape

  • 06.1. Market overview
  • 06.2. Market size and forecast
  • 06.3. Five forces analysis

07. Benign Prostatic Hyperplasia: An Overview

  • 07.1. Incidence and prevalence
  • 07.2. Major symptoms

08. Market Segmentation by Procedure

  • 08.1. TURP
  • 08.2. Laser surgery
  • 08.3. TUMT
  • 08.4. TUNA
  • 08.5. Prostatic stenting
  • 08.6. Others

09. Geographical Segmentation

  • 09.1. Benign prostatic hyperplasia devices market in Americas
    • 09.1.1. Market size and forecast
  • 09.2. Benign prostatic hyperplasia devices market in EMEA
    • 09.2.1. Market size and forecast
  • 09.3. Benign prostatic hyperplasia devices market in APAC
    • 09.3.1. Market size and forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and Their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and Their Impact

17. Vendor Landscape

  • 17.1. Competitive scenario
    • 17.1.1. Key news
  • 17.2. Vendor analysis 2014
  • 17.3. Other prominent vendors

18. Key Vendor Analysis

  • 18.1. Endo International
    • 18.1.1. Key facts
    • 18.1.2. Business overview
    • 18.1.3. Business segmentation by revenue 2013
    • 18.1.4. Business segmentation by revenue 2012 and 2013
    • 18.1.5. Geographical segmentation by revenue 2013
    • 18.1.6. Business strategy
    • 18.1.7. Recent developments
    • 18.1.8. SWOT analysis
  • 18.2. Karl Storz
    • 18.2.1. Key facts
    • 18.2.2. Business overview
    • 18.2.3. Business segmentation
    • 18.2.4. Business strategy
    • 18.2.5. Key developments
    • 18.2.6. SWOT analysis
  • 18.3. Lumenis
    • 18.3.1. Key facts
    • 18.3.2. Business overview
    • 18.3.3. Business segmentation by revenue 2013
    • 18.3.4. Business segmentation by revenue 2012 and 2013
    • 18.3.5. Geographical segmentation by revenue 2013
    • 18.3.6. Business strategy
    • 18.3.7. Recent developments
    • 18.3.8. SWOT analysis
  • 18.4. Olympus
    • 18.4.1. Key facts
    • 18.4.2. Business overview
    • 18.4.3. Business segmentation by revenue 2013
    • 18.4.4. Sales by geography
    • 18.4.5. Business strategy
    • 18.4.6. Key developments
    • 18.4.7. SWOT analysis
  • 18.5. Urologix
    • 18.5.1. Key facts
    • 18.5.2. Business overview
    • 18.5.3. Business strategy
    • 18.5.4. SWOT analysis

19. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market research methodology
  • Exhibit 2: Global benign prostatic hyperplasia devices market 2014-2019 ($ millions)
  • Exhibit 3: Storage symptoms of benign prostatic hyperplasia
  • Exhibit 4: Voiding symptoms of benign prostatic hyperplasia
  • Exhibit 5: Segmentation of global benign prostatic hyperplasia devices market by procedure
  • Exhibit 6: Segmentation of global benign prostatic hyperplasia devices market by procedure 2014
  • Exhibit 7: Market analysis of various procedures 2014
  • Exhibit 8: Segmentation of global benign prostatic hyperplasia devices market by geography 2014
  • Exhibit 9: Benign prostatic hyperplasia devices market in Americas 2014-2019 ($ millions)
  • Exhibit 10: Benign prostatic hyperplasia devices market in EMEA 2014-2019 ($ millions)
  • Exhibit 11: Benign prostatic hyperplasia devices market in APAC 2014-2019 ($ millions)
  • Exhibit 12: Segmentation of global benign prostatic hyperplasia devices market by geography 2014-2019
  • Exhibit 13: Global benign prostatic hyperplasia devices market: YoY growth rate 2014-2019
  • Exhibit 14: Major drivers of global benign prostatic hyperplasia devices market
  • Exhibit 15: Major challenges in global benign prostatic hyperplasia devices market
  • Exhibit 16: Major trends in global benign prostatic hyperplasia devices market
  • Exhibit 17: Endo Health Solutions: Key takeaways
  • Exhibit 18: Karl Storz: Key takeaways
  • Exhibit 19: Lumenis: Key takeaways
  • Exhibit 20: Olympus: Key takeaways
  • Exhibit 21: Urologix: Key takeaways
  • Exhibit 22: Endo International: Business segmentation by revenue 2013
  • Exhibit 23: Endo International: Business segmentation by revenue 2012 and 2013 ($ millions)
  • Exhibit 24: Endo International: Geographical segmentation by revenue 2013
  • Exhibit 25: Karl Storz: Business segmentation
  • Exhibit 26: Lumenis: Business segmentation by revenue 2013
  • Exhibit 27: Lumenis: Business segmentation by revenue 2012 and 2013 ($ millions)
  • Exhibit 28: Lumenis: Geographical segmentation by revenue 2013
  • Exhibit 29: Olympus: Business segmentation by revenue 2013
  • Exhibit 30: Olympus: Sales by geography 2013
Back to Top